source
- Zanidatamab shows strong single-agent activity in HER2-positive gastric and biliary cancersZanidatamab, a dual HER2-binding antibody, demonstrated notable efficacy as a single agent in studies of gastric and biliary tract cancers. The activity was described as striking, suggesting that…
- Experts preview promising triple-negative breast cancer studies for ASCO 2026At the 2026 ASCO Annual Meeting, leading breast cancer specialists highlighted the triple-negative breast cancer (TNBC) abstracts they consider most likely to influence clinical practice. The disc…